← All trials
NCT06400537
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2024
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2026
- First posted
- May 6, 2024
- Last posted
- Oct 24, 2024
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologySponsor investigator
- Huazhong University of Science and TechnologyOfficial
- ITabMed Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.